258 related articles for article (PubMed ID: 19772377)
41. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
Attia IA; El-Gizawy SA; Fouda MA; Donia AM
AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527
[TBL] [Abstract][Full Text] [Related]
42. Mucoadhesive tablets for controlled release of acyclovir.
Ruiz-Caro R; Gago-Guillan M; Otero-Espinar FJ; Veiga MD
Chem Pharm Bull (Tokyo); 2012; 60(10):1249-57. PubMed ID: 22863800
[TBL] [Abstract][Full Text] [Related]
43. Effect of Hydrophilic Polymers on the Release Rate and Pharmacokinetics of Acyclovir Tablets Obtained by Wet Granulation: In Vitro and In Vivo Assays.
Venkatesh DN; Meyyanathan SN; Kovacevic A; Zielińska A; Fonseca J; Eder P; Dobrowolska A; Souto EB
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235026
[TBL] [Abstract][Full Text] [Related]
44. The effect of sucrose and salts in combination on the drug release behaviour of an HPMC matrix.
Williams HD; Ward R; Hardy IJ; Melia CD
Eur J Pharm Biopharm; 2010 Nov; 76(3):433-6. PubMed ID: 20837144
[TBL] [Abstract][Full Text] [Related]
45. Assembled modules technology for site-specific prolonged delivery of norfloxacin.
Oliveira PR; Bernardi LS; Strusi OL; Mercuri S; Segatto Silva MA; Colombo P; Sonvico F
Int J Pharm; 2011 Feb; 405(1-2):90-6. PubMed ID: 21134427
[TBL] [Abstract][Full Text] [Related]
46. In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery.
Gandhi A; Jana S; Sen KK
Int J Biol Macromol; 2014 Jun; 67():478-82. PubMed ID: 24755259
[TBL] [Abstract][Full Text] [Related]
47. Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir.
Al-Dhubiab BE; Nair AB; Kumria R; Attimarad M; Harsha S
Colloids Surf B Biointerfaces; 2015 Dec; 136():878-84. PubMed ID: 26547315
[TBL] [Abstract][Full Text] [Related]
48. Enhanced dissolution performance of curcumin with the use of supersaturatable formulations.
Gosangari S; Dyakonov T
Pharm Dev Technol; 2013; 18(2):475-80. PubMed ID: 22881446
[TBL] [Abstract][Full Text] [Related]
49. Effect of HPMC concentration on β-cyclodextrin solubilization of norfloxacin.
Loh GO; Tan YT; Peh KK
Carbohydr Polym; 2014 Jan; 101():505-10. PubMed ID: 24299805
[TBL] [Abstract][Full Text] [Related]
50. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
Stella B; Arpicco S; Rocco F; Burgalassi S; Nicosia N; Tampucci S; Chetoni P; Cattel L
Eur J Pharm Biopharm; 2012 Jan; 80(1):39-45. PubMed ID: 22008147
[TBL] [Abstract][Full Text] [Related]
51. Development and optimization of controlled release bioerodable anti infective ophthalmic insert.
Thakur R; Swami G; Rahman M
Curr Drug Deliv; 2014; 11(1):2-10. PubMed ID: 22283654
[TBL] [Abstract][Full Text] [Related]
52. Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E₂-induced ocular inflammation.
Mathurm M; Gilhotra RM
Drug Deliv; 2011 Jan; 18(1):54-64. PubMed ID: 20718601
[TBL] [Abstract][Full Text] [Related]
53. Modulated dissolution rate from the inclusion complex of antichagasic benznidazole and cyclodextrin using hydrophilic polymer.
Sá-Barreto LC; Gustmann PC; Garcia FS; Maximiano FP; Novack KM; Cunha-Filho MS
Pharm Dev Technol; 2013; 18(5):1035-41. PubMed ID: 22200091
[TBL] [Abstract][Full Text] [Related]
54. Preparation and characterization of TAM-loaded HPMC/PAN composite fibers for improving drug-release profiles.
Shen X; Yu D; Zhang X; Branford-White C; Zhu L
J Biomater Sci Polym Ed; 2011; 22(16):2227-40. PubMed ID: 21083974
[TBL] [Abstract][Full Text] [Related]
55. Formulation and physicochemical characterization of chitosan/acyclovir co-crystals.
Allam AN; Naggar VF; El Gamal SS
Pharm Dev Technol; 2013; 18(4):856-65. PubMed ID: 21749270
[TBL] [Abstract][Full Text] [Related]
56. Optimization of acyclovir oral tablets based on gastroretention technology: factorial design analysis and physicochemical characterization studies.
El Gamal SS; Naggar VF; Allam AN
Drug Dev Ind Pharm; 2011 Jul; 37(7):855-67. PubMed ID: 21401342
[TBL] [Abstract][Full Text] [Related]
57. Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide.
Verma P; Gupta RN; Jha AK; Pandey R
Drug Deliv; 2013; 20(7):269-76. PubMed ID: 24044644
[TBL] [Abstract][Full Text] [Related]
58. Multicomponent complexes of piroxicam with cyclodextrins and hydroxypropyl methylcellulose.
Jug M; Bećirević-Laćan M
Drug Dev Ind Pharm; 2004; 30(10):1051-60. PubMed ID: 15595571
[TBL] [Abstract][Full Text] [Related]
59. The development of sustained release drug delivery platforms using melt-extruded cellulose-based polymer blends.
Wilson MR; Jones DS; Andrews GP
J Pharm Pharmacol; 2017 Jan; 69(1):32-42. PubMed ID: 27747867
[TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo evaluation of a matrix-in-cylinder system for sustained drug delivery.
Mehuys E; Vervaet C; Gielen I; Van Bree H; Remon JP
J Control Release; 2004 Apr; 96(2):261-71. PubMed ID: 15081217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
